europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

Joint Statement: The Data Act is a leap into the unknown

01/02/2023
POSITION PAPER

1 February 2023

Data sharing will be fundamental to the success of the European economy in the coming years, with data contributing at least €1 trillion by 2030. But the Data Act as it stands is a huge leap into the unknown, affecting the fundamentals of European companies’ data-driven business models, with only the promise of a better data future.

As the policymaking process accelerates on this pivotal proposal, industry warns against possible unintended economic consequences across data value chains.

At a time of great economic upheaval, record-high energy prices and the negative impact of pandemic and war on global supply chains, what industry needs to succeed is stability, not more uncertainty. Before opening Pandora’s box, the Data Act’s rules need to be tried and tested in real-world market conditions to make sure that they work for European businesses.

The opposite result will be achieved if the Data Act rushes to impose widespread data sharing onto unsuspecting businesses already overwhelmed by an unprecedented amount of new regulation.

The European Parliament and Council should take sufficient time to preserve European innovation and competitiveness. Concretely, they must ensure that the proposal:

  • Protects trade secrets, safety, security and privacy by including effective safeguards to prevent data misuse and unfair competition;
  • Gives certainty to companies as to if and what they must share, starting by setting clear definitions, e.g. ‘data’ and ‘data holder’;
  • Enables companies to find mutually beneficial data-driven relationships by recognising the central role of flexible contractual terms, including on compensation;
  • Differentiates between the business-to-business (B2B) and the business-to-consumer (B2C) contexts and provides different rules and safeguards accordingly;
  • Sets strict conditions to business-to-government (B2G) data requests and limits the scope to public emergencies, to avoid endless litigation and uncertainty for Member States;
  • Promotes cloud adoption through an applicable and adaptable switching framework that reflects technical reality and market needs, and provides legal clarity;
  • Does not create new obstacles to international data flows, which are critical to European companies’ operation and growth in foreign markets;
  • Allows for a longer transition period, of at least 36 months, to give companies time to prepare, and does not apply retroactively to ensure predictability of current investments.

We trust that EU policymakers will take the time to build a framework that supports Europe’s data economy.

Joint statement: The Data Act is a leap into the unknown


Download
2020_12_G_PP_Comitology Joint StatementDownload

Share
Alexandra Simionca
Alexandra Simionca

Related posts

28/02/2023

How do we live in a bioeconomy? EuropaBio at the Swedish EU Council Presidency conference


Read more
23/02/2023

EuropaBio Response to Public Consultation on Horizon Europe – interim evaluation


Read more
17/02/2023

Inter-association letter to raise our concern about the proposed definition of “natural polymers” in the REACH restriction of microplastics


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member